Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
Saijo
N
N
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
Nishio
K
K
Ohta
S
S
Arioka
H
H
Funayama
Y
Y
Fukuoka
K
K
Kurokawa
H
H
Nomoto
T
T
Ishida
T
T
Yamamoto
N
N
Tamura
T
T
Shinkai
T
T
Eguchi
K
K
Ohe
Y
Y
Kunito
H
H
Ohtsu
T
T
Sasaki
Y
Y
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007564:Japan; D008869:Microtubule-Associated Proteins / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D043823:Taxoids; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014751:Vindesine / Q000627:therapeutic use*; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D008869:Microtubule-Associated Proteins; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine; D014751:Vindesine